[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3504210T3 - 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych - Google Patents

7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Info

Publication number
PL3504210T3
PL3504210T3 PL17758527T PL17758527T PL3504210T3 PL 3504210 T3 PL3504210 T3 PL 3504210T3 PL 17758527 T PL17758527 T PL 17758527T PL 17758527 T PL17758527 T PL 17758527T PL 3504210 T3 PL3504210 T3 PL 3504210T3
Authority
PL
Poland
Prior art keywords
prophylaxis
treatment
virus infection
substituted
compounds
Prior art date
Application number
PL17758527T
Other languages
English (en)
Inventor
Lu Gao
Chungen Liang
Hongying Yun
Xiufang ZHENG
Jianping Wang
Kun MIAO
Bo Zhang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3504210T3 publication Critical patent/PL3504210T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17758527T 2016-08-29 2017-08-28 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych PL3504210T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12
PCT/EP2017/071514 WO2018041763A1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
EP17758527.0A EP3504210B1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
PL3504210T3 true PL3504210T3 (pl) 2021-07-05

Family

ID=59738346

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17758527T PL3504210T3 (pl) 2016-08-29 2017-08-28 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Country Status (30)

Country Link
US (3) US10233184B2 (pl)
EP (2) EP3865482A1 (pl)
JP (2) JP7013467B2 (pl)
KR (2) KR20220147702A (pl)
CN (1) CN109641904B (pl)
AU (3) AU2017320742B2 (pl)
BR (1) BR112019003519A2 (pl)
CA (1) CA3034148A1 (pl)
CL (1) CL2019000512A1 (pl)
CO (1) CO2019000932A2 (pl)
CR (1) CR20190087A (pl)
DK (1) DK3504210T3 (pl)
ES (1) ES2867849T3 (pl)
HR (1) HRP20210621T1 (pl)
HU (1) HUE053944T2 (pl)
IL (3) IL284255B (pl)
MA (1) MA46038B1 (pl)
MX (2) MX2019002129A (pl)
MY (1) MY197408A (pl)
PE (1) PE20190476A1 (pl)
PH (1) PH12019500432A1 (pl)
PL (1) PL3504210T3 (pl)
PT (1) PT3504210T (pl)
RS (1) RS61752B1 (pl)
RU (1) RU2751349C2 (pl)
SG (2) SG11201901633WA (pl)
SI (1) SI3504210T1 (pl)
TW (1) TWI671300B (pl)
UA (1) UA124270C2 (pl)
WO (1) WO2018041763A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738352B2 (ja) * 2015-05-08 2020-08-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych
CA3034185A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
EP3758707A1 (en) * 2018-02-28 2021-01-06 F. Hoffmann-La Roche AG 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
AU2020358726A1 (en) 2019-10-01 2022-04-07 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
AU2021231160A1 (en) 2020-03-02 2022-09-22 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Name of the invention: antibody conjugates against ASGR1 and their uses
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
WO2022031057A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도
CN114315861A (zh) * 2020-09-27 2022-04-12 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
GB202306325D0 (en) 2023-04-28 2023-06-14 Iksuda Therapeutics Ltd Antibody-drug conjugate compounds, and methods of use and treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
CA2230808C (en) 1996-07-03 2006-08-15 Japan Energy Corporation A novel purine derivative
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
AU732361B2 (en) * 1997-11-28 2001-04-26 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compounds
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
WO2004006867A2 (en) 2002-03-15 2004-01-22 Wayne State University 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents
ES2387388T3 (es) * 2002-09-27 2012-09-21 Dainippon Sumitomo Pharma Co., Ltd. Compuesto de adenina y uso del mismo
BRPI0611435A2 (pt) 2005-05-04 2010-09-08 Pfizer Ltd derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
ES2541434T3 (es) * 2007-06-29 2015-07-20 Gilead Sciences, Inc. Derivados de purina y su uso como moduladores del receptor de tipo Toll 7
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
JP5600116B2 (ja) * 2008-12-09 2014-10-01 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体のモジュレーター
EP2491035B1 (en) * 2009-10-22 2017-08-30 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
PT3190113T (pt) 2014-08-15 2021-06-17 Chai Tai Tianqing Pharmaceutical Group Co Ltd Compostos pirrolopirimidina utilizados como agonistas de tlr7
JP6738352B2 (ja) * 2015-05-08 2020-08-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Also Published As

Publication number Publication date
PT3504210T (pt) 2021-04-19
US10752630B2 (en) 2020-08-25
CN109641904A (zh) 2019-04-16
RU2019107957A (ru) 2020-09-29
JP2019526633A (ja) 2019-09-19
KR102459155B1 (ko) 2022-10-28
MA46038B1 (fr) 2021-05-31
HRP20210621T1 (hr) 2021-05-28
US20180072730A1 (en) 2018-03-15
KR20220147702A (ko) 2022-11-03
MA46038A (fr) 2019-07-03
HUE053944T2 (hu) 2021-08-30
IL264710B (en) 2021-07-29
CA3034148A1 (en) 2018-03-08
KR20190039829A (ko) 2019-04-15
EP3504210B1 (en) 2021-02-24
SI3504210T1 (sl) 2021-08-31
PH12019500432A1 (en) 2019-10-21
MX2021006902A (es) 2021-07-07
NZ750604A (en) 2024-02-23
IL284255B (en) 2022-07-01
US20190256515A1 (en) 2019-08-22
RS61752B1 (sr) 2021-05-31
MX2019002129A (es) 2019-06-20
CL2019000512A1 (es) 2019-07-12
ES2867849T3 (es) 2021-10-21
JP7013467B2 (ja) 2022-01-31
EP3865482A1 (en) 2021-08-18
US10233184B2 (en) 2019-03-19
CO2019000932A2 (es) 2019-02-08
AU2017320742A1 (en) 2019-02-28
CN109641904B (zh) 2022-01-28
CR20190087A (es) 2019-04-30
RU2019107957A3 (pl) 2020-12-18
EP3504210A1 (en) 2019-07-03
PE20190476A1 (es) 2019-04-04
BR112019003519A2 (pt) 2019-05-21
AU2021204303A1 (en) 2021-07-22
TW201819382A (zh) 2018-06-01
WO2018041763A1 (en) 2018-03-08
TWI671300B (zh) 2019-09-11
JP2022050632A (ja) 2022-03-30
SG10202010520SA (en) 2020-11-27
RU2751349C2 (ru) 2021-07-13
IL284255A (en) 2021-07-29
IL293475B1 (en) 2024-06-01
US20200385387A1 (en) 2020-12-10
AU2021204303B2 (en) 2022-05-12
IL293475B2 (en) 2024-10-01
AU2022204697A1 (en) 2022-07-21
SG11201901633WA (en) 2019-03-28
MY197408A (en) 2023-06-16
JP7214900B2 (ja) 2023-01-30
AU2017320742B2 (en) 2021-08-05
UA124270C2 (uk) 2021-08-18
DK3504210T3 (da) 2021-04-26
IL293475A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
IL284255A (en) 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
HK1251554A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
HUS2200053I1 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
HK1251221A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的三環4-吡啶酮-3-甲酸衍生物
HK1251220A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的四環4-氧代-吡啶-3-甲酸衍生物
HK1223931A1 (zh) 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL280769A (en) New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
ZA201900770B (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt) Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection